Provides relative to pharmaceutical costs (OR +$153,127 GF EX See Note)
Impact
The proposed law would significantly impact state healthcare regulations and practices. It requires drug manufacturers to report comprehensive data regarding production, research and development, and marketing costs for any drug placed on the critical prescription drug list. This will facilitate better understanding and analysis of drug costs, helping legislators and health officials to develop informed recommendations for minimizing prescription drug costs while ensuring access and quality of care for consumers in Louisiana.
Summary
House Bill 918 seeks to address prescription drug costs in Louisiana by mandating the Louisiana Department of Health to compile and maintain a list of critical prescription drugs that are of substantial public interest. The bill stipulates that this list should consider various factors, including the drugs' costs to public health programs, availability, alternative treatments, and their treatment outcomes. By holding manufacturers accountable for reporting detailed pricing and cost information, the bill aims to enhance transparency surrounding drug pricing.
Sentiment
General sentiment towards HB 918 appears to be supportive among public health advocates who argue that it will reinforce consumer protection measures and possibly lead to lower drug prices. However, there is also caution among some stakeholders who fear that the extensive reporting requirements may overburden manufacturers and impact their research and development capabilities. The discussions around the bill reflect a balance between the need for transparency in pricing and the potential implications for pharmaceutical innovation.
Contention
Key points of contention include the confidentiality provisions outlined in the bill, which some argue may undermine the bill's goal of transparency by restricting access to detailed financial data. Additionally, the requirement for manufacturers to disclose extensive pricing information could lead to resistance from the pharmaceutical industry, with concerns raised about how these regulations might affect drug availability and market competition. The debate emphasizes the challenge of balancing transparency in drug pricing with the operational realities of pharmaceutical manufacturing.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a sixty-day (60) supply may be dispensed at any one time.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a ninety-day (90) supply may be dispensed at any one time.